Johnson & Johnson Seeks Global Nominees for Award Geared at Female Researchers Working in Science, Technology, Engineering, Math, Manufacturing and Design

Johnson & Johnson (NYSE: JNJ) today announced it is accepting applications for its 2022 Women in STEM 2 D (WiSTEM 2 D) Scholars Award. The award, which aims to support assistant or associate academic professors in the disciplines of Science, Technology, Engineering, Math, Manufacturing and Design, provides recipients with three years of mentorship from leaders at Johnson & Johnson and a total $150,000 ( $50,000 each year). The deadline for applications is September 27, 2021 at 9 a.m. HST and guidelines and additional details are available here: https:www.JNJ.comwistem2d-university-scholars .

Launched in June 2017 , the Johnson & Johnson WiSTEM 2 D Scholars Award aspires to fuel development of female STEM 2 D leaders, and inspire career paths in STEM 2 D, by supporting the research of the awarded women in their respective STEM 2 D fields.

"COVID-19 has shown us that investments in research are critical to advance health for humanity and, as we begin to emerge from the pandemic, there is a great need for continued progress and innovation aimed at a healthier, safer and more equitable world," said Cat Oyler, Vice President, Clinical Transformation, Immunology and Integration Leader, Momenta Pharmaceuticals, Inc. and WiSTEM 2 D University Sponsor. "Research shows that the pandemic disproportionally affected women in WiSTEM 2 D, with 70% unable to obtain funding, making this award more crucial than ever."

An independent External Advisory Board will select the 2022 winners, each of whom will represent one of the STEM 2 D disciplines. Last year, more than 650 highly qualified applicants from across the world applied for the award.

In order to apply for the 2022 WiSTEM 2 D Scholars Award, the applicant must:

  • Submit a university or school department head letter of recommendation ( Each University/Institution can support one applicant per STEM 2 D discipline; 6 applicants in total ).
  • Write 1,000 words detailing the proposed area of research. One additional page can be added for images, or references.
  • Submit her resume (three pages, font size 11), including a list of publications, presentations, abstracts, current financial support already obtained, other folio work and two references.
  • Submit a brief outline of the budget for proposed research.

For more information and to apply for the 2022 Awards, visit: https://www.jnj.com/wistem2d-university-scholars .

About Johnson & Johnson WiSTEM   2   D  
Building a diverse STEM 2 D community is one approach Johnson & Johnson is taking as part of a broader effort to accelerate the development of women leaders and support women at all stages of their life to improve global health and well-being and drive sustainable economic growth. Johnson & Johnson launched the WiSTEM 2 D (Women in Science, Technology, Math, Manufacturing and Design) program in 2015 to increase the representation of women in science and technical fields. The program's multifaceted approach is designed to engage females at three pivotal development stages in their lives:

  • Youth Programs (Ages 5 to 18 years): Johnson & Johnson is partnering with organizations to align curriculum in schools, augment program-based learning and engage Johnson &
  • Johnson employees around the world as mentors to students.
    University Talent: Johnson & Johnson is partnering with leading academic institutions to develop high-impact strategies for increasing the number of women enrolling in and graduating with STEM 2 D programs and degrees. At the graduate level, Johnson & Johnson has implemented to STEM 2 D Scholars Award to increase the number of women pursuing research in STEM 2 D fields.
  • Professionals: Johnson & Johnson is identifying and implementing best practices for attracting and retaining the world's best technical female talent in STEM 2 D careers.

About Johnson & Johnson  
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at www.JNJ.com. Follow us at @JNJNews.

Cautions Concerning Forward-Looking Statements  
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding development of a potential preventive vaccine for COVID-19. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies, and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021 , including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

Media Contacts:
Michael Nge , APCO Worldwide
mnge@apcoworldwide.com

Maggie McGarvey , APCO Worldwide
mmcgarvey@apcoworldwide.com

Cision View original content: https://www.prnewswire.com/news-releases/johnson--johnson-seeks-global-nominees-for-award-geared-at-female-researchers-working-in-science-technology-engineering-math-manufacturing-and-design-301363760.html

SOURCE Johnson & Johnson

News Provided by PR Newswire via QuoteMedia

The Conversation (0)

Medtronic announces cash dividend for third quarter of fiscal year 2025

The board of directors of Medtronic plc (NYSE: MDT) on Thursday, December 5, 2024, approved the company's cash dividend for the third quarter of fiscal year 2025 of $0 .70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on January 10, 2025 to shareholders of record at the close of business on December 27, 2024 .

About Medtronic
Bold thinking. Bolder actions. We are Medtronic . Medtronic plc , headquartered in Galway , Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic , visit www.Medtronic.com and follow Medtronic on LinkedIn .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Cardiex Limited (ASX:CDX)

Cardiex Limited


Keep reading...Show less

Global Medical Service Robotics Market Project to Exceed $20 Billion in 2024 with Additional Growth Expected

FN Media Group News Commentary - Innovations in robotics technology, including artificial intelligence machine learning, and sensor technology, are enhancing the capabilities of medical robots. These advancements enable more precise surgical procedures, improved rehabilitation processes, and efficient hospital logistics, thus attracting more healthcare facilities to adopt robotic solutions. The market is characterized by a moderate level of merger and acquisition (M&A) activity by the leading players. This is due to several factors, including the desire to expand the business to cater to the growing demand for medical service robots. A report from Grand View Research said that the global medical service robots market size was estimated at USD 20.59 billion in 2024 and is projected to grow at a CAGR of 16.5% from 2025 to 2030. It said: "The growth can be attributed to the introduction of technologically advanced robotic equipment in the healthcare sector and the rise in per capita healthcare spending. Continuous advancements in technology, such as robotic catheter control systems (CCS), data recorders, data analytics, remote navigation, motion sensors, 3D-Imaging, and HD surgical microscopic cameras, are projected to drive industry growth. Furthermore, the introduction of swarm robotics is opening new opportunities for industry. It is a new approach to coordinating multi-robotic systems through swarm intelligence." Active Tech Companies in the markets today include Jeffs' Brands Ltd (NASDAQ: JFBR), Serve Robotics Inc. (NASDAQ: SERV), Symbotic Inc. (NASDAQ: SYM), Microbot Medical Inc. (NASDAQ: MBOT), Medtronic plc (NYSE: MDT).

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Healing People and Planet: 3 Things You Need to Know About This Shared Innovation Challenge

By Ken Washington, Chief Technology and Innovation Officer, and Raman Venkatesh, Chief Sustainability Officer, Medtronic

When you think about healthcare technology, you may imagine the pacemaker assisting your dad's ailing heart, the sutures your child received after a bike accident, or the pulse oximeter placed on your finger during your annual physical exam. You probably don't think about the energy or resources required to manufacture those products, nor the resulting emissions and waste.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Healing People and Planet: New Impact Report Outlines How Medtronic Is Shaping the Future of Health

Medtronic

Medtronic releases 2024 Impact Report highlighting success in healthcare equity with new data from the Healthy Neighbor program, in addition to community engagement and environmental sustainability progress

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×